NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both in-vitro and in-vivo. Based on proprietary Cybin technologies, more than 20 definitive research studies designed by the company’s scientists were completed in record time. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved…